AUROPHARMA
15.11.2022 - CITI on Auropharma Maintain Buy CMP 491.8 Target 660
16.08.2022 - CLSA on Auropharma Maintain Buy CMP 583.8 Target 710
16.08.2022 - CS on Auropharma Maintain Outperform CMP 583.8 Target 720
01.06.2022 - CLSA on Auropharma Maintain Buy CMP 534.2 Target 700
01.06.2022 - CS on Auropharma Maintain Outperform CMP 534.2 Target 790
01.06.2022 - GS on Auropharma Maintain Buy CMP 534.2 Target 720
29.03.2022 - BOFA on Auropharma Maintain Buy CMP 675.75 Target 845
11.02.2022 - CS on Auropharma Maintain Outperform CMP 684 Target 855
CREDIT SUISSE ON AUROBINDO : 14.07.2021
• Higher growth trajectory and improving RoCE to drive re-rating
• Increase FY22/23E EPS by 7%/8% and introduce FY24E
• High growth in FY24 reflects benefits of multiple growth drivers
* Generic injectables is now a large segment for Aurobindo
CS ON AUROBINDO PHARMA : 14.07.2021
* CS maintains Outperform call on Aurobindo Pharma with target being raised to rs 1,230/sh
* MAINTAIN OUTPERFORM TARGET: 1,230
• Increase FY22/23 EPS Estimates By 7%/8%
* High Growth In FY24 Reflects Benefits Of Multiple Growth Drivers
JPMORGAN ON AUROBINDO PH : 01.06.2021
* MAINTAIN OVERWEIGHT TARGET: 1,100
* Another good quarter for Aurobindo Pharma despite higher R&D; core business visibility + injectable optionality to support stock, JPMorgan says
* Another Good Quarter Despite Higher R&D
* Core Business Visibility + Injectable Optionality To Support Stock
* Merging Unit 16 W/Eugia A Step Closer To Exploring Value-unlocking Options
CLSA ON AUROBINDO PHARMA : 01.06.2021
* DOWNGRADE OUTPERFORM FROM BUY TARGET: 1,040 (PREVIOUS TARGET: 1.000)
* CLSA downgrades Aurobindo Pharma to OUTPERFORM from BUY, lowers FY23 EPS estimate by 2%
* Complex Product Pipeline Development Should Increase Medium-term R&D Spend
* Lower Our FY23 EPS Estimate By 2%
CS ON AUROBINDO PHARMA : 01.06.2021
* MAINTAIN OUTPERFORM TARGET: 1,080
* Credit Suisse likes Aurobindo Pharma's stock on account of large injectable biz, improving quality of filings. Here's more by the brokerage on the pharma co
* Good Injectable Play; Vaccine Opportunity Delayed
* Like The Stock On A/c Of Large Injectable Biz, Improving Quality Of Filings
* Like It On China opportunity & Bulk Drugs PLI scheme
GOLDMAN SACHS ON AUROBINDO PHARMA : 01.06.2021
* Maintain BUY, Target at Rs 1,140/share
* R&D ramps up to support complex pipeline
* Aurobindo reported a broadly in-line 4Q21
* Global injectable sales of US$111mn were up +2% QoQ
* Margins remained stable QoQ, despite the jump in R&D
* Trim our FY22-24 EPS estimates by up to 5% to factor in slower margin development